Heparine Leo

Heparine Leo is a prescription injectable medication that contains heparin sodium as its active ingredient. The product is supplied in an injectable form for intravenous administration; the specific strength is not disclosed in the available data. Classified as an anticoagulant, Heparine Leo is marketed in the European Union and is used under medical supervision to manage conditions that require inhibition of blood clot formation for therapeutic purpose.

Heparine Leo is indicated for several clinical situations where anticoagulation is required.

- Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Prophylaxis of deep‑vein thrombosis in patients undergoing orthopedic or general surgery. - Anticoagulation during cardiac surgery procedures such as cardiopulmonary bypass. - Management of acute coronary syndrome when rapid anticoagulation is needed. - Use as an adjunct in extracorporeal circulation or dialysis circuits to maintain circuit patency.

Adverse reactions to Heparine Leo can vary in frequency and severity; they are typically categorized as common or serious.

Common: - Minor bleeding at the injection site or bruising. - Small hematomas. - Mild nausea or vomiting. - Transient elevation of liver enzymes. - Localized pain at the injection site. - Transient hypotension.

Serious: - Major hemorrhage, including internal bleeding. - Heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as urticaria, angioedema, or anaphylaxis.

When prescribing Heparine Leo, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess baseline coagulation parameters and platelet count before initiating therapy. - Adjust dose in patients with renal or hepatic impairment. - Use caution in individuals with a history of heparin‑induced thrombocytopenia. - Monitor for signs of bleeding, especially in surgical or trauma patients. - Avoid use during pregnancy unless benefits outweigh risks; category B indicates limited data. - Consider age‑related dosing adjustments for elderly patients. - Review concomitant use of other anticoagulants or antiplatelet agents.

Heparine Leo may interact with other medications that affect hemostasis or platelet function, requiring careful management.

Avoid: - Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors) due to additive bleeding risk. - Combination with systemic thrombolytic agents (e.g., alteplase) without dose adjustment. - Simultaneous administration of high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding tendency.

Use with caution: - Co‑administration with oral anticoagulants such as warfarin; monitor INR closely. - Use alongside antiplatelet drugs (clopidogrel, ticagrelor); observe for enhanced hemorrhagic effects. - Concomitant therapy with drugs that may cause thrombocytopenia (e.g., quinine, carbamazepine).